Fidelity Management & Research, an investment manager, led a $85m Series G funding round in PROCEPT BioRobotics, a manufacturer of medical and surgical equipment. The round had participation from investors T. Rowe Price Associates, CPMG, Perceptive Advisors, Viking Global Investors and Duquesne Family Office. "Aquablation's combination of safety and efficacy provide millions of men dealing with the disease of BPH an option that addresses the tradeoffs that exist with current treatment options. We would like to welcome both Fidelity Management & Research Company LLC and T. Rowe Price Associates as shareholders to our company and thank our existing investors for their continued support. We expect this capital will enable us to continue scaling our commercialization efforts to meet the global demand for Aquablation," Reza Zadno, PROCEPT BioRobotics President and CEO.